Patents by Inventor Jennifer Anne Nicki

Jennifer Anne Nicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE
    Publication number: 20240100153
    Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.
    Type: Application
    Filed: November 10, 2023
    Publication date: March 28, 2024
    Inventors: Yuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
  • Human cytomegalovirus GB polypeptide
    Patent number: 11857622
    Abstract: The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof. In some embodiments, the mutant is stabilized in a conformation alternative to the gB postfusion conformation.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: January 2, 2024
    Assignee: Pfizer Inc.
    Inventors: Yuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
  • Human cytomegalovirus gB polypeptide
    Patent number: 11629172
    Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: April 18, 2023
    Assignee: Pfizer Inc.
    Inventors: Philip Ralph Dormitzer, Ye Che, Xiaoyuan Sherry Chi, Seungil Han, Kyle Paul Heim, Thomas Richard Jones, Yuhang Liu, Xiayang Qiu, Xinzhen Yang, Xiaojie Yao, Matthew Curtis Griffor, Jennifer Anne Nicki
  • HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE
    Publication number: 20220088184
    Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.
    Type: Application
    Filed: June 17, 2021
    Publication date: March 24, 2022
    Inventors: Yuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
  • HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDE
    Publication number: 20200247853
    Abstract: The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.
    Type: Application
    Filed: December 19, 2019
    Publication date: August 6, 2020
    Inventors: Philip Ralph Dormitzer, Ye Che, Xiaoyuan Sherry Chi, Seungil Han, Kyle Paul Heim, Thomas Richard Jones, Yuhang Liu, Xiayang Qiu, Xinzhen Yang, Xiaojie Yao, Matthew Curtis Griffor, Jennifer Anne Nicki